Schedule 13G - Passive Investments
NASDAQ
SCHEDULE 13G/A: JPMorgan Chase & Co. Amends Passive Stake in Alterity Therapeutics, Reports 4.0% Ownership
JPMorgan Chase & Co. has filed an Amendment No. 1 to its Schedule 13G, disclosing a 4.0% passive beneficial ownership stake in Alterity Therapeutics Limited as of April 30, 2025.
NASDAQ
JPMorgan Chase & Co. has disclosed a 6.3% passive beneficial ownership stake in Alterity Therapeutics Limited, as reported in a recent Schedule 13G filing.